Minsheng Securities: First rate JD Health (06618.HK) with a "recommendation" rating, Q3 revenue and profit growth strong.

Wisdom Financial APP learned that Minsheng Securities released a research report stating that JD Health (06618.HK) showed strong growth in revenue and profits in the third quarter of 2025, with further accelerating growth rate. The company has expanded its coverage through medical insurance payment, offline service expansion, and deepening layout of AI medical applications, consolidating its leading position in pharmaceutical e-commerce. The potential for growth of JD Health is optimistic, and Minsheng Securities initiated coverage with a "recommended" rating.